A Bioavailability Study of Nilotinib in Healthy, Adult, Human Subjects Under Fasted Conditions.
brief summary
An open label, single-center, balanced, randomized, four-treatment, four-sequence, four-period, single dose, crossover, comparative bioavailability study in healthy, adult, human subjects under fasteding conditions
detailed description
To evaluate the relative bioavailability of XS003 capsules 2x48mg (96mg) versus Tasigna 200 mg, and XS003 capsules 4x48mg versus Tasigna 400 mg after a single dose under fasted conditions in healthy, adult, human subjects.
official title
An Open-label, Randomized, Four-treatment, Four-period, Four-sequence, Single Dose, Crossover Study to Evaluate the Dose Adjusted Relative Bioavailability of Nilotinib Following the Oral Administration of Tasigna 200 mg Capsules, Tasigna 400 mg, XS003 (Nilotinib) Capsules 96mg and 192mg in Healthy, Adult Subjects Under Fasted Conditions